NCT07088081View on ClinicalTrials.gov

Evaluation of Efficacy and Safety of Immune Check Point Inhibitors in Hepatocellular Carcinoma Patients in Ain Shams University Hospitals

Enrolling by invitationOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

July 31, 2026

Conditions
HCC - Hepatocellular CarcinomaImmunotherapyImmune Checkpoint TherapyImmune Checkpoint Inhibitor-Induced DermatitisAtezolizumab and Bevacizumab in Hepatocellular CarcinomaDurvalumab
Trial Locations (1)

00202

Ain Shams University, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER